Inositolized Phospholipids as Antiproliferative Agents

<strong>Background</strong><br>

Phospholipid analogues with high metabolic stability have been synthesized and proven to be successful as anti-proliferative agents. Due to negative side effects efforts have been made to synthesize phospholipids that are less cytotoxic.<br><br> <strong>Technology</strong><br> We offer a novel class of synthetic phospholipids, a method for preparing the phospholipids and their use for the treatment of proliferating diseases such as psoriasis and cancer. <br><br> The effectiveness of the synthetic ether phospholipid Ino-C2-PAF has been assessed in vitro and in vivo. In vitro studies with cancer cells and keratino-cytes revealed strong anti-proliferative and anti-inflammatory effects. Fur-thermore, in vivo studies in a mouse model of psoriasis (K5.hTGFß) proofed that Ino-C2-PAF has great therapeutic potential without having mutagenic or toxic side-effects. <br><br> Thus, these results position Ino-C2-PAF as an exciting new therapeutic agent for psoriasis.<br><br> <strong>Benefits</strong><br> <ul> <li>strong anti-proliferative and anti-inflammatory effects</li> <li>no mutagenic and no toxic side-effects</li> <li>wide spectrum of application including cancer and psoriasis</li> </ul><br> <strong>IP Rights</strong><br> Patent granted in US, JP, DE, CH, ES, FR, GB, IT (priority 11/2002); <br> Patent pending in CA<br><br> <strong>Patent Owner</strong><br> Charité – Universitätsmedizin Berlin

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz